Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1374.55
28.30 (2.10%)
< Home < Back

Maharashtra FDA suspends 2 drug licenses of Dr Reddy's Laboratories: Report

Date: 08-01-2015

Maharashtra Food & Drug Administration (FDA) has reportedly issued a notice to suspend two drug licenses of Dr Reddy's Laboratories for violations and serious lapses at its storage premises at Bhiwandi near Thane.  The two drugs have been suspended from January 12 to February 10, 2015 under rules 66 (1) and 67 (H) of the Drugs & Cosmetics Act, 1940.

Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.